RT Journal Article
SR Electronic
T1 Vaccination saves lives: How do patients with chronic diseases and severe COVID-19 fare? Analysis from India’s National Clinical registry for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.22.22276744
DO 10.1101/2022.06.22.22276744
A1 Mukherjee, Aparna
A1 Kumar, Gunjan
A1 Turuk, Alka
A1 Bhalla, Ashish
A1 Bingi, Thrilok Chander
A1 Bhardwaj, Pankaj
A1 Baruah, Tridip Dutta
A1 Mukherjee, Subhasis
A1 Talukdar, Arunansu
A1 Ray, Yogiraj
A1 John, Mary
A1 Khambholja, Janakkumar R
A1 Patel, Amit H.
A1 Bhuniya, Sourin
A1 Joshi, Rajnish
A1 Menon, Geetha R
A1 Sahu, Damodar
A1 Rao, Vishnu Vardhan
A1 Bhargava, Balram
A1 Panda, Samiran
YR 2022
UL http://medrxiv.org/content/early/2022/06/27/2022.06.22.22276744.abstract
AB Objectives This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalised COVID-19 adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC).Methods NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1st September 2020 to 26th October 2021 were examined.Results Analysis of 29,509 hospitalised, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18752 (63.6%)] showed that 15678 (53.1%) had at least one comorbidity. Among 25715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n=3957). Adjusted odds of dying were significantly higher in age-group ≥60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy, and tuberculosis, presenting with dyspnea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6, 7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4, 0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3, 0.7)] were protected from in-hospital mortality.Conclusions WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.icmr.gov.in/tab1ar1.html Funding StatementAM, GK, AT, LKS, SP are employed by the Indian Council of Medical Research, the funding source of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from the Central Ethics Committee for Human Research at ICMR as well as from the respective Institutional Ethics Committee of each of the participating centres.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs the project is currently ongoing, the data is not being shared. Though data can be shared, with a formal proposal sent to the corresponding author.